


下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemENemorubicinhydrochlorideCat.No.:HY-15794ACASNo.:108943-08-4Synonyms:Methoxymorpholinyldoxorubicinhydrochloride;FCE23762hydrochloride;PNU152243A分?式:C??H??ClNO??分?量:680.1作?靶點:G-quadruplex作?通路:CellCycle/DNADamage儲存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Nemorubicinhydrochloride?種阿霉素衍?物,具有抗腫瘤活性。Nemorubicinhydrochloride不僅插?到雙鏈DNA中,?且還產(chǎn)?了G-四聯(lián)體(G-quadruplex)重的配體,使其結(jié)構(gòu)穩(wěn)定。體外研究Nemorubicinhydrochloridehasantitumoractivity,withIC70sof578±137nM,468±45nM,193±28nM,191±19nM,68±12nM,and131±9nMforHT-29,A2780,DU145,EM-2,JurkatandCEMcelllines,respectively[1].Nemorubicinactsthroughnucleotideexcisionrepair(NER)systemtoexertitsactivity.Nemorubicin(0-0.3μM)ismoreactiveintheL1210/DDPcellswithintactNERthanintheXPG-deficientL1210/0cells.CellsresistanttonemorubicinshowincreasedsensitivitytoUVdamage[3].Nemorubiciniscytotoxicto9L/3A4cells,withanIC50of0.2nM,120-foldlowerthanthatofP450-deficient9Lcells(IC50,23.9nM).NemorubicinalsopotentlyinhibitsAdeno-3A4infectedU251cellswithIC50of1.4nM.P450reductaseoverexpressionenhancescytotoxicityofNemorubicin[4].體內(nèi)研究NemorubicinisconvertedtoPNU-159682byhumanlivercytochromeP450(CYP)3A4inrat,mouse,anddoglivermicrosomes[2].Nemorubicin(60μg/kg)inducessifnificanttumorgrowthdelayinscidmicebearing9L/3A4tumors,butshowsnoobviouseffectonthetumorgrowthdelayof9Ltumorsinmicebyi.v.orintratumoralinjection(i.t.).Nemorubicin(40μg/kg,i.p.)exhibitsnoantitumoractivityandnohosttoxicityinmicebearing9L/3A4tumors[4].PROTOCOL1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemECellAssay[4]9LandCHOcellsareplatedintriplicatewellsofa96-wellplateat3000cellsperwell24hrpriortodrugtreatment.CellsaretreatedwithvariousconcentrationsofNemorubicinorIFAfor4d.Cellsarethenstainedwithcrystalviolet(A595)andrelativecellsurvivaliscalculated.IC50valuesaredeterminedfromasemi-logarithmicgraphofthedatapointsusingPrism4[4].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.Animal9Land9L/3A4cellsaregrownassolidtumorsinmaleICR/FoxChaseSCIDmice.CellsculturedinDMEMAdministration[4]mediumto75%confluencearetrypsinizedandwashedinPBSandthenadjustedto2×107cells/mLofFBS-freeDMEM.Four-week-oldSCIDmice(18-20g)areimplantedwitheither9Lor9L/3A4tumorcellsbyinjectionof4×106cells/0.2mLofcellsuspension,s.c.oneachhindflank.Tumorsizes(lengthandwidth)aremeasuredtwiceaweekusingVerniercalipersbeginning7daftertumorimplantation.Whentheaveragetumorsizereach300to400mm3,NemorubicindissolvedinPBSisadministeredbytailveininjection(i.v.)orbydirectintratumoral(i.t.)injection(threeinjectionsspaced7dapart,eachat60μgNemorubicinperkgbodyweight).Intratumoralinjectionsareperformedusingasyringepumpseta1μL/switha30-gaugeneedle.Eachi.t.treatmentdoseisdividedintothreeinjectionspertumor,withtheinjectedvolumesetat50μLpertumorper25gmouse.Thus,fora30gmouse,atotalof120μLof15μg/mLofNemorubicinsolutionisadministered:20μLpersite×3sitespertumor×2tumors/mouse.Drug-freecontrolsareinjectedi.t.withthesamevolofPBS.Insomeexperiments,Nemorubicinisadministeredbyi.p.injectionat40or60μg/kgbodyweight.Tumorsizesandbodyweightsaremeasuredtwice/wkforthedurationofthestudy.Tumorvolumesarecalculatedusingtheformula:V=π/6(L×W)3/2.Percenttumorregressioniscalculatedas100×(V1-V2)/V1,whereV1isthetumorvolonthedayofdrugtreatmentandV2isthevolonthedaywhenthelargestthedecreaseintumorsizeisseenfollowingdrugtreatment.Tumordoublingtimeiscalculatedasthetimerequiredfortumorstodoubleinvolafterdrugtreatment[4].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Patent.US20240261422A1.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].QuintieriL,etal.FormationandantitumoractivityofPNU-159682,amajormetaboliteofnemorubicininhumanlivermicrosomes.ClinCancerRes.2005Feb15;11(4):1608-17.[2].QuintieriL,etal.InvitrohepaticconversionoftheanticanceragentnemorubicintoitsactivemetabolitePNU-159682inmice,ratsanddogs:acomparisonwithhumanlivermicrosomes.BiochemPharmacol.2008Sep15;76(6):784-95.[3].SabatinoMA,etal.Down-regulationofthenucleotideexcisionrepairgeneXPGasanewmechanismofdrugresistanceinhumanandmurinecancercells.MolCancer.2010Sep24;9:259.[4].LuH,etal.PotentiationofmethoxymorpholinyldoxorubicinantitumoractivitybyP4503A4genetransfer.CancerGeneTher.2009May;16(5):393-404.McePdfHeigh
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年廊坊道路運輸貨運考試題庫
- 低壓電工科目三題庫
- 2025年寶雞貨運資格證題庫及答案大全
- 航空業(yè)的飛行員許可要求
- 2025年國際貿(mào)易合同樣本中英文對照
- 2025年昌吉貨運從業(yè)資格考試
- 2025企業(yè)設(shè)備購買擔(dān)保合同
- 2025臨時工勞動合同
- 2025監(jiān)理工程師《合同管理》考點合同違約責(zé)任2
- 冬季切痣護(hù)理方法
- 2025年《宏觀經(jīng)濟(jì)政策與發(fā)展規(guī)劃》考前通關(guān)必練題庫(含答案)
- 服裝公司品質(zhì)(質(zhì)量)管理手冊
- 一年級道德與法治下冊素養(yǎng)教案第10課 相親相愛一家人
- 辦公樓弱電系統(tǒng)設(shè)計方案
- 私募投資學(xué)試題及答案
- 2025年合肥二模數(shù)學(xué)試題及答案
- 不要慌太陽下山有月光二部合唱簡譜
- 干凈整潔的個人衛(wèi)生習(xí)慣
- 光伏補(bǔ)貼申請流程
- 小數(shù)與單位換算(說課稿)-2023-2024學(xué)年四年級下冊數(shù)學(xué)人教版
- 實驗診斷學(xué)練習(xí)題庫(附參考答案)
評論
0/150
提交評論